Related Experiment Video

Updated: May 29, 2026

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

DNA intercalator korkormicin A preferentially kills tumor cells expressing wild type p53

Jirouta Kitagaki1, Yili Yang

  • 1Cancer and Developmental Biology Laboratory, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.

Biochemical and Biophysical Research Communications
|September 28, 2011
PubMed

Insights

Korkormicin A, a cyclic depsipeptide, shows potent antitumor activity by intercalating DNA and activating p53. This natural compound preferentially induces apoptosis in cancer cells with wild-type p53, indicating therapeutic potential.

Area of Science:

  • Natural Products Chemistry
  • Molecular Pharmacology
  • Cancer Biology

Background:

  • Korkormicin A is a cyclic depsipeptide with demonstrated antitumor properties.
  • Understanding its mechanism of action is crucial for developing novel cancer therapeutics.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying korkormicin A's antitumor activity.
  • To investigate korkormicin A's interaction with DNA and its effects on cellular pathways.

Main Methods:

  • DNA intercalation assays.
  • Western blotting to assess p53 phosphorylation and degradation.
  • Cell-based assays to evaluate apoptosis induction in transformed and untransformed cells.

Main Results:

  • Korkormicin A binds to DNA via intercalation.
  • It induces p53 phosphorylation, inhibiting p53 degradation and activating p53-dependent transcription.
  • Preferential induction of apoptosis in transformed cells with wild-type p53.

Conclusions:

  • Korkormicin A's mechanism involves DNA intercalation and p53 pathway modulation.
  • Its ability to selectively induce apoptosis in wild-type p53 cancer cells highlights its therapeutic promise.
  • Korkormicin A represents a potential novel agent for treating cancers characterized by wild-type p53.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...